Open AccessSystemic Inflammation Response Index is a Prognostic Risk Factor in Patients with Hepatocellular Carcinoma Undergoing TACE
Author(s) -
Tian-Cheng Wang,
Tian-Zhi An,
Junxiang Li,
Pengfei Pang
Publication year - 2021
Publication title -
risk management and healthcare policy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.828
H-Index - 22
ISSN - 1179-1594
DOI - 10.2147/rmhp.s316740
Subject(s) - medicine , hepatocellular carcinoma , receiver operating characteristic , logistic regression , oncology , gastroenterology , biomarker , systemic inflammation , inflammation , biochemistry , chemistry
Mounting evidence has shown that systemic inflammation response index (SIRI), a novel prognostic biomarker based on peripheral lymphocyte, neutrophil and monocyte counts, is associated with poor prognosis for several tumors. However, the prognostic value of SIRI in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) is elusive. Herein, we aimed to evaluate the correlation between SIRI and clinical outcomes in these patients.